These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 25761680)
1. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics. Zvereva MI; Zatsepin TS; Azhibek DM; Shubernetskaya OS; Shpanchenko OV; Dontsova OA Biochemistry (Mosc); 2015 Mar; 80(3):251-9. PubMed ID: 25761680 [TBL] [Abstract][Full Text] [Related]
2. How to inhibit telomerase activity for cancer therapy. Kyo S; Inoue M Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728 [TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Rankin AM; Faller DV; Spanjaard RA Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043 [TBL] [Abstract][Full Text] [Related]
4. Telomerase inhibition, oligonucleotides, and clinical trials. Corey DR Oncogene; 2002 Jan; 21(4):631-7. PubMed ID: 11850789 [TBL] [Abstract][Full Text] [Related]
5. Targeting human telomerase in cancer therapy. Huard S; Autexier C Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Tárkányi I; Aradi J Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408 [TBL] [Abstract][Full Text] [Related]
11. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Kelland LR Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745 [TBL] [Abstract][Full Text] [Related]
12. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]. Raymond E; Faivre S; Dieras V; Von Hoff D Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365 [TBL] [Abstract][Full Text] [Related]
13. Telomerase inhibitors in cancer therapy: current status and future directions. Incles CM; Schultes CM; Neidle S Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225 [TBL] [Abstract][Full Text] [Related]
14. Telomeres and telomerase as targets for anticancer drug development. Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501 [TBL] [Abstract][Full Text] [Related]
15. Telomerase: a target for cancer therapeutics. Shay JW; Wright WE Cancer Cell; 2002 Oct; 2(4):257-65. PubMed ID: 12398889 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Glukhov AI; Zimnik OV; Gordeev SA; Severin SE Biochem Biophys Res Commun; 1998 Jul; 248(2):368-71. PubMed ID: 9675142 [TBL] [Abstract][Full Text] [Related]
17. [Telomeres and telomerase as targeted therapies in cancer treatment]. Souiden Y; Bouraoui A; Chaieb K; Mahdouani K Bull Cancer; 2010 Sep; 97(9):1087-104. PubMed ID: 20663741 [TBL] [Abstract][Full Text] [Related]
18. Recent patents on anti-telomerase cancer therapy. Agrawal A; Dang S; Gabrani R Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):102-17. PubMed ID: 21854360 [TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors. Herbert BS; Pongracz K; Shay JW; Gryaznov SM Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790 [TBL] [Abstract][Full Text] [Related]